Inactive Instrument

News Sonoma Pharmaceuticals Inc Nasdaq

Equities

US83558L1052

Summary

Unlock all the news on all businesses: Never miss an investment opportunity again!

Sonoma Pharmaceuticals Announces Expansion of Negative-Pressure Wound Therapy Products for Use in the United States	Apr. 10	AQ
Sonoma Pharmaceuticals Reports Recent Publication from Australia Highlighting Potential for Microdox in Managing Urinary Tract Infections	Apr. 05	AQ
Sonoma Pharmaceuticals Highlights Safety Advantages of its Microcyn Products in Light of Growing Concerns of Benzene in Many Other Topicals	Mar. 28	AQ
Sonoma Pharmaceuticals Reports Third Fiscal Quarter 2024 Financial Results	Feb. 09	AQ
Sonoma Pharmaceuticals, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2023	Feb. 08	CI
Sonoma Pharmaceuticals Introduces Lumacyn Clarifying Mist, an All Natural, Over-The-Counter Skincare Product for Daily Use	Jan. 23	CI
NovaBay Pharmaceuticals and Sonoma Pharmaceuticals Agree to Market Avenova-branded Products in the European Union through Sonoma's Extensive Distributor Network	Jan. 10	AQ
NovaBay Pharmaceuticals and Sonoma Pharmaceuticals Agree to Market Avenova-branded Products in the European Union Through Sonoma?s Extensive Distributor Network	Jan. 09	CI
Sonoma Pharmaceuticals : Material Agreement - Form 8-K	Dec. 18	PU
Sonoma Pharmaceuticals, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2023	Nov. 13	CI
Sonoma Pharmaceuticals, Inc. Announces U.S. Launch of Next Generation Advanced Solution for Pulse Lavage Irrigation At the Symposium on Advanced Wound Care Fall Conference	Nov. 03	CI
Sector Update: Health Care Stocks Ease in Late Afternoon	23-10-26	MT
Sector Update: Health Care	23-10-26	MT
Top MIdday Decliners	23-10-26	MT
Wall Street Set to Open Lower as GDP, Jobless Claims Higher Than Expected	23-10-26	MT
Sonoma Pharmaceuticals : Investor Presentation October 2023 - Form 8-K	23-10-11	PU
Ladenburg Thalmann Initiates Coverage on Sonoma Pharmaceuticals at Buy, $3.25 Price Target	23-09-05	MT
National Eczema Association Awards Seal of Acceptance to Sonoma Pharmaceuticals for Reliefacyn Advanced	23-08-16	AQ
National Eczema Association Awards Seal of Acceptance to Sonoma Pharmaceuticals, Inc. for Reliefacyn Advanced	23-08-15	CI
Sonoma Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended June 30, 2023	23-08-10	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

News Sonoma Pharmaceuticals Inc Nasdaq

Equities

US83558L1052

Summary

Filters